Growth Hormone Deficiency in Children

Endocrinology
2
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
5 programs
2
SomapacitanPhase 31 trial
somapacitanPhase 31 trial
No treatment givenN/A1 trial
Norditropin® FlexPro®N/A1 trial
SomapacitanN/A1 trial
Active Trials
NCT03672617Completed321Est. Apr 2019
NCT03972345Enrolling By Invitation750Est. Jun 2031
NCT06109935Enrolling By Invitation200Est. Jul 2026
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Novo Nordisksomapacitan
Novo NordiskSomapacitan
Novo NordiskSomapacitan
Novo NordiskNorditropin® FlexPro®
Novo NordiskNo treatment given

Clinical Trials (5)

Total enrollment: 1,581 patients across 5 trials

NCT04970654Novo Nordisksomapacitan

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Start: Jul 2021Est. completion: Dec 2023110 patients
Phase 3Completed
NCT03811535Novo NordiskSomapacitan

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

Start: May 2019Est. completion: Sep 2025200 patients
Phase 3Completed
NCT06109935Novo NordiskSomapacitan

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Start: Oct 2023Est. completion: Jul 2026200 patients
N/AEnrolling By Invitation
NCT03972345Novo NordiskNorditropin® FlexPro®

Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Start: Jun 2019Est. completion: Jun 2031750 patients
N/AEnrolling By Invitation
NCT03672617Novo NordiskNo treatment given

Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy

Start: Oct 2018Est. completion: Apr 2019321 patients
N/ACompleted

Related Jobs in Endocrinology

Research Associate I/II - Biology

Marea Therapeutics
South San Francisco
1w ago
$90K - $120K/yr

Associate Director, Clinical Operations

Marea Therapeutics
South San Francisco
3w ago
$190K - $210K/yr

Associate Director/Director, Regulatory Affairs

Marea Therapeutics
South San Francisco
1mo ago
$185K - $240K/yr

Medical Science Liaison (rare diseases)

Amgen
Poland - Lódz
1mo ago

Senior/Executive Director, Analytical Development

Marea Therapeutics
South San Francisco
1mo ago
$250K - $295K/yr

Senior Clinical Scientist - Job ID: 1845

Ascendis Pharma
Palo Alto, California (Hybrid)
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Acromegaly(67)Growth Hormone Deficiency(39)Growth Hormone Disorder(37)Hypogonadism(21)Secondary Hyperparathyroidism(13)Hypoparathyroidism(12)Thyroid Eye Disease(11)Adult Growth Hormone Deficiency(10)Hypothyroidism(9)Cushing's Syndrome(9)